|
Slide |
Credits |
1 |
Facts |
2 |
|
3 |
Guidelines |
4 |
|
5 |
Guideline Compliance |
6 |
Guideline Problems |
7 |
Pathophysiology |
8 |
Airway Inflammation |
9 |
NHLBI: Key Indicators |
10 |
|
11 |
Historical Features |
12 |
|
13 |
NHLBI: Key Indicators |
14 |
Physical Exam |
15 |
NHLBI: Key Indicators |
16 |
Spirometry |
17 |
|
18 |
Spirometry in Asthma |
19 |
Spirometry |
20 |
Peak Flow Monitoring |
21 |
Differential Diagnosis |
22 |
|
23 |
Other Studies |
24 |
Airway Hyper-responsiveness |
25 |
Methacholine Challenge |
26 |
Bronchoprovocation |
27 |
Other Studies |
28 |
Vocal Cord Dysfunction |
29 |
Asthma Therapy |
30 |
Drug Therapy |
31 |
Classification of Asthma |
32 |
|
33 |
Mild Intermittent |
34 |
|
35 |
Classification of Asthma |
36 |
Mild Persistent |
37 |
|
38 |
Classification of Asthma |
39 |
Moderate Persistent |
40 |
|
41 |
|
42 |
Classification of Asthma |
43 |
Severe Persistent |
44 |
|
45 |
Beta Agonists |
46 |
Inhaled Corticosteroids |
47 |
|
48 |
Toxicity of Inhaled Steroids |
49 |
Therapy Failure |
50 |
Leukotriene Inhibitors |
51 |
Reference |
52 |
|
53 |
Patient Characteristics |
54 |
Classification of Asthma |
55 |
Conclusions |
56 |
|
57 |
Long Acting Beta Agonists |
58 |